Verenium Corporation

Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

Retrieved on: 
tisdag, maj 7, 2024
Sale, Prospectus, Executive, IP, MDB, Verenium Corporation, AI, BASF, Business development, QIAGEN, Business, Life, CLC, Form, IPO, DNA, Science, Synthetic biology, SABS, QGEN, Electronics, POET, Person, Energy, Management

MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team.

Key Points: 
  • He also currently serves as Chairman of the Board for EXO Incubator Inc. (private) and BlueSEQ Innovations Inc. (private).
  • "Invizyne’s SimplePathTM platform represents the first biomanufacturing technology that I have come across that overcomes the issues of other cell-based synthetic biology approaches,” said Michael Helzten, CEO of Invizyne.
  • The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
  • Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol "IZTC."

Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

Retrieved on: 
tisdag, maj 7, 2024
Sale, Prospectus, Executive, IP, MDB, Verenium Corporation, AI, BASF, Energy transition, Business development, QIAGEN, Business, Life, CLC, Form, IPO, DNA, Science, Synthetic biology, SABS, QGEN, Electronics, POET, Person, Energy, Management

He also currently serves as Chairman of the Board for EXO Incubator Inc. (private) and BlueSEQ Innovations Inc. (private).

Key Points: 
  • He also currently serves as Chairman of the Board for EXO Incubator Inc. (private) and BlueSEQ Innovations Inc. (private).
  • “By using cell-free enzyme systems to produce biochemicals, we believe Invizyne can also significantly create new useful drugs and chemicals that can be commercially produced at competitive prices.
  • The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
  • Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol "IZTC."

Michael Burns Joins Invizyne as Executive Vice President of Energy Transition

Retrieved on: 
onsdag, november 8, 2023
Carbon, Bryant University, Energy transition, U.S. Department of Energy, Office of Inspector General, Bio Products Laboratory, Enzyme, BASF, Aviation, Nature Communications, Western New England University, U.S. Department of Defense Strategy for Operating in Cyberspace, Synthetic biology, Verenium Corporation, MDB, Renewable energy, Novozymes

Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.

Key Points: 
  • Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
  • "Michael Burns brings two decades worth of business strategy and development, global licensing, project development, and project finance expertise in the sustainable energy and synthetic biology industries to Invizyne.
  • We are honored to have an executive with his gravitas and experience join the team to head up our new Energy Transition business unit,” said Mo Hayat, CEO of Invizyne.
  • He also served in strategy and development roles at Verenium Corporation, a specialized enzyme biotechnology company that was acquired by BASF.

Plant Geneticist and Molecular Biology Expert Eric Mathur Joins ONIT Sciences as Chief Science Officer

Retrieved on: 
måndag, januari 16, 2023
Cattle, Synthetic Genomics (company), Dow, Monsanto, Syngenta, SG Biofuels, Molecular biology, Systems ecology, DNA, Verenium Corporation, Health, BASF, Bacteria, Research, Food industry, Agriculture, Cannabis, Coffee, Jatropha

IRVINE Calif., Jan. 16, 2023 /PRNewswire/ -- ONIT Sciences, an agriculture company specializing in organic input technologies, announced today that Eric Mathur, a globally recognized plant geneticist and molecular biologist, has been named the company's Chief Science Officer. Mathur is a subject matter expert in crop improvement and has conducted research worldwide in the industrial plant sciences arena. His skill sets and knowledge traverse genome sciences, molecular biology, plant molecular breeding, environmental microbiology and agricultural biotechnology. His expertise, industry network and insights into plant health make him the perfect professional to lead ONIT's research, development and sales support initiatives.

Key Points: 
  • Mathur is a subject matter expert in crop improvement and has conducted research worldwide in the industrial plant sciences arena.
  • His skill sets and knowledge traverse genome sciences, molecular biology, plant molecular breeding, environmental microbiology and agricultural biotechnology.
  • His expertise, industry network and insights into plant health make him the perfect professional to lead ONIT's research, development and sales support initiatives.
  • Mathur's career spans over 40 years with focus on translational science, making significant advances in plant sciences research.

Industry Leading Protein Design Company, Arzeda, Expands Leadership Team with Addition of Ken Barrett and Scott Fabro

Retrieved on: 
onsdag, april 13, 2022
Trident, Protein, CEO, Biotechnology, Fortune 500, LLC, High, Enzyme, Fabro, Bain & Company, Machine learning, BASF, Verenium Corporation, Barrett, Growth, Food, Fusion Global Business Solutions, Beauty, Bain, Company, Mitsubishi Motors, New business development, Solution, Business, Partnership, Business development, SA, Senior, CPG, Cargill, Time, Head, Management, Fine chemical

SEATTLE, April 13, 2022 /PRNewswire/ -- Arzeda, the industry-leading Protein Design Company™, today announced the expansion of its commercial team with the appointments of Ken Barrett as Chief Business Officer and Scott Fabro as Senior Vice President of Food Ingredients. The addition of Barrett and Fabro advances the company's growth and commercialization strategy of its portfolio of enzymes within the consumer personal care and home products and food industries.

Key Points: 
  • The addition of Barrett and Fabro advances the company's growth and commercialization strategy of its portfolio of enzymes within the consumer personal care and home products and food industries.
  • "We're thrilled to have both Ken and Scott join the Arzeda team.
  • In addition, Fabro spent three years with Evolva Group, SA, where he was Chief Operations Officer and before that, Chief Commercial Officer.
  • Arzeda's proprietary protein design platform combines physics-based computational protein design, machine learning, and lab automation to expand the reach of biotechnology beyond the solutions that nature evolved.

ArrePath Appoints Michael Dudley, PharmD, Chairman, Board of Directors

Retrieved on: 
torsdag, mars 24, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, University, Sequah Medicine Company, C1-inhibitor, Insight Partners, UCSF, Multimedia, Board, Doctor of Pharmacy, Global health, Research, Doctor of Philosophy, CSO, Pepperdine University, CEO, Verenium Corporation, Health, Industry, Acquisition, University of California, San Francisco, Boron, Hartford Hospital, Infection, Princeton University, FDA, Pharmaceutical industry, Pharmacy, Cell, Biology

ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Companys Board of Directors.

Key Points: 
  • ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Companys Board of Directors.
  • We look forward to his guidance and insights on our Board as we advance our machine-learning-based platform for the discovery of new and differentiated classes of anti-infectives.
  • ArrePath is building an exceptional team and pursuing a highly innovative strategy using modern tools and approaches to antimicrobial drug discovery.
  • I welcome the opportunity to work with the ArrePath team and its Board.

Metabolon Announces Chief Financial Officer Transition

Retrieved on: 
måndag, februari 14, 2022
Impulse, Health, Metabolomics, Business, CEO, Biomarker, CFO, Business administration, MRCY, Kurtzweil, Nasdaq, ISO, Technology, Mercury Systems, Verenium Corporation, Precision, Lipidomics, Cornell Law School, LinkedIn, Medtech, Twitter, CLIA, BP, Publication, Genetic variation, Sale, BASF, Growth, Research, Drug discovery, GLOBE, Diet, Management, Science, Metabolon

MORRISVILLE, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Metabolon ,Inc., the global leader in metabolomics, announces the appointment of Gerald M. Haines II as Chief Financial Officer (CFO), as current CFO John Kurtzweil prepares to retire.

Key Points: 
  • MORRISVILLE, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Metabolon ,Inc., the global leader in metabolomics, announces the appointment of Gerald M. Haines II as Chief Financial Officer (CFO), as current CFO John Kurtzweil prepares to retire.
  • Haines and Kurtzweil will partner in the coming weeks for a seamless transition, with Haines assuming full-time responsibilities effective April 1, 2022.
  • As we approach this transition, I am also grateful for John Kurtzweils many contributions during his tenure and thank him for supporting a smooth handover.
  • Haines joins Metabolon from Impulse Dynamics, where he served as Executive Vice President and CFO since 2019.